glp-1 heart failure reduced ejection fraction REAL WORLD OUTCOMES OF GLUCAGON LIKE PEPTIDE1 RECEPTOR AGONISTS (GLP1-RA) IN DIABETIC PATIENTS WITH AND Gut Hormones in Heart Failure

Risk factors include the speed and magnitude of weight loss, pre-existing nutritional deficiencies, age, sex (women are more commonly affected), and individual genetic susceptibility

The Cleveland Clinic study found that 27% of people who stopped their GLP-1 switched to a different medication within 12 months

Its decline accelerates the sarcopenic process that estrogen withdrawal initiates, reducing the metabolically active tissue that both burns energy at rest and supports functional independence in later life

For the study, WashU Medicine researchers analyzed de-identified medical records in a database maintained by the U.S

GLP-1RAs, via the incretin pathway, stimulate the release of insulin as well as decrease the release of glucagon [2]